Cipher Pharmaceuticals (STU:PHE) E10: €0.26 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PHE Cipher Pharmaceuticals Inc STU:PHE
89 GF Score
Price €8.70
GF Value €10.49
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Cipher Pharmaceuticals E10?

Cipher Pharmaceuticals STU:PHE -1.14% 89 E10 is €0.26 as of Jun. 2026. GuruFocus rates STU:PHE with a GF Score™ of 89/100 and a GF Value™ of €10.49 (Modestly Undervalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cipher Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was €0.130. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.26 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Cipher Pharmaceuticals's average E10 Growth Rate was -100.00% per year. During the past 3 years, the average E10 Growth Rate was 12.80% per year. During the past 5 years, the average E10 Growth Rate was 38.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Cipher Pharmaceuticals was 97.20% per year. The lowest was 0.00% per year. And the median was 23.90% per year.

As of today (2026-08-14), Cipher Pharmaceuticals's current stock price is €8.70. Cipher Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 was €0.26. Cipher Pharmaceuticals's Shiller PE Ratio of today is 33.46.

During the past 13 years, the highest Shiller PE Ratio of Cipher Pharmaceuticals was 316.00. The lowest was 13.67. And the median was 30.67.


Cipher Pharmaceuticals  (STU:PHE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cipher Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=8.70/0.26
=33.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Cipher Pharmaceuticals was 316.00. The lowest was 13.67. And the median was 30.67.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cipher Pharmaceuticals E10 Related Terms


Cipher Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Cipher Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipher Pharmaceuticals E10 Chart

Cipher Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.16 0.15 0.13 0.20

Cipher Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.17 0.20 0.24 0.26

STU:PHE vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipher Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cipher Pharmaceuticals's Shiller PE Ratio falls into.


STU:PHE
89GF Score
Cipher Pharmaceuticals Inc STU:PHE
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipher Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cipher Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.13/133.5265*133.5265
=0.130

Current CPI (Jun. 2026) = 133.5265.

Cipher Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201609 -0.722 101.765 -0.947
201612 -0.408 101.449 -0.537
201703 -0.122 102.634 -0.159
201706 0.036 103.029 0.047
201709 0.084 103.345 0.109
201712 0.118 103.345 0.152
201803 -0.041 105.004 -0.052
201806 0.068 105.557 0.086
201809 0.026 105.636 0.033
201812 -0.035 105.399 -0.044
201903 0.027 106.979 0.034
201906 0.044 107.690 0.055
201909 -0.073 107.611 -0.091
201912 0.099 107.769 0.123
202003 0.090 107.927 0.111
202006 0.018 108.401 0.022
202009 0.051 108.164 0.063
202012 -0.008 108.559 -0.010
202103 0.042 110.298 0.051
202106 0.083 111.720 0.099
202109 0.026 112.905 0.031
202112 0.089 113.774 0.104
202203 0.073 117.646 0.083
202206 0.076 120.806 0.084
202209 0.101 120.648 0.112
202212 0.717 120.964 0.791
202303 0.093 122.702 0.101
202306 0.111 124.203 0.119
202309 0.253 125.230 0.270
202312 0.275 125.072 0.294
202403 0.184 126.258 0.195
202406 0.111 127.522 0.116
202409 0.009 127.285 0.009
202412 0.124 127.364 0.130
202503 0.092 129.181 0.095
202506 0.191 129.892 0.196
202509 0.179 130.287 0.183
202512 0.436 130.366 0.447
202603 0.208 132.262 0.210
202606 0.130 133.527 0.130

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.26 mean?
Cipher Pharmaceuticals (STU:PHE) has a E10 of €0.26 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cipher Pharmaceuticals and its competitors.
Is Cipher Pharmaceuticals' E10 too high?
Cipher Pharmaceuticals' current E10 is €0.26. Overall, Cipher Pharmaceuticals has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' E10 compare to ZTS?
Cipher Pharmaceuticals' E10 of €0.26 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cipher Pharmaceuticals and its competitors. Cipher Pharmaceuticals's current E10 is €0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (STU:PHE) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.49, compared to a current price of €8.70 — trading 17.1% below its estimated fair value. The current E10 is €0.26. Cipher Pharmaceuticals' overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Cipher Pharmaceuticals (STU:PHE), the current E10 is €0.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipher Pharmaceuticals (STU:PHE) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of €8.70 is trading 17.1% below its estimated GF Value™ of €10.49. GuruFocus considers Cipher Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:PHE:

  • E10: €0.26
  • GF Value™: €10.49 vs. price of €8.70 (17.1% below fair value)
  • GF Score™: 89/100 with 7 warning signs

No single metric tells the full story. See the STU:PHE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cipher Pharmaceuticals Business Description

Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
89GF Score

Get the complete analysis for STU:PHE

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.70
Price
€10.49
GF Value